Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Express Scripts
Boehringer Ingelheim
Moodys
Medtronic

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ifetroban

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Ifetroban: Sponsors, patents, clinical trial progress

Ifetroban is an investigational drug.

There have been 9 clinical trials for Ifetroban. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2011.

The most common disease conditions in clinical trials are Respiratory Tract Diseases, Respiration Disorders, and Asthma, Aspirin-Induced. The leading clinical trial sponsors are Cumberland Pharmaceuticals, Jeffrey Rade, and American Heart Association.

There are six hundred and thirty-eight US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Ifetroban
TitleSponsorPhase
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionAmerican Heart AssociationPhase 2
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionCumberland PharmaceuticalsPhase 2
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionJeffrey RadePhase 2

See all Ifetroban clinical trials

Clinical Trial Summary for Ifetroban

Top disease conditions for Ifetroban
Top clinical trial sponsors for Ifetroban

See all Ifetroban clinical trials

US Patents for Ifetroban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ifetroban   See Pricing Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   See Pricing
Ifetroban   See Pricing Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer Capella Therapeutics, Inc. (San Diego, CA)   See Pricing
Ifetroban   See Pricing Compositions and methods of treating cardiac fibrosis with ifetroban Cumberland Pharmaceuticals Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)   See Pricing
Ifetroban   See Pricing Substituted biaryl sulfonamides and the use thereof NovoMedix, LLC (San Diego, CA)   See Pricing
Ifetroban   See Pricing Compositions and methods of treating muscular dystrophy with thromboxane-A.sub.2 receptor antagonists Cumberland Pharmaceuticals, Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ifetroban

Drugname Country Document Number Estimated Expiration Related US Patent
Ifetroban China 103987697 2031-10-14   See Pricing
Ifetroban European Patent Office 2766345 2031-10-14   See Pricing
Ifetroban European Patent Office 2899183 2031-10-14   See Pricing
Ifetroban Spain 2572908 2031-10-14   See Pricing
Ifetroban Spain 2699226 2031-10-14   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Johnson and Johnson
McKesson
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.